Ertapenem

Penem Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Ertapenem is an ofp drug in the Penem Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 2001. DrugCentral lists 8 molecular targets, including pbpA, Penicillin-binding protein 4 and dacA. Recorded indications include Abdominal abscess, Acute bacterial peritonitis, Bacterial pneumonia and Bacteroides Septic Abortion.

• Approval status: ofp (first approved 2001 by the FDA).
• Drug class: Penem Antibacterial.
• Molecular targets: pbpA, Penicillin-binding protein 4, dacA and ponA (8 listed in DrugCentral).
• Indications: Abdominal abscess, Acute bacterial peritonitis, Bacterial pneumonia, Bacteroides Septic Abortion and Colorectal Surgery Infection Prevention and others.
• ATC code: J01DH03 (Carbapenems).
• Molecular formula: C22H25N3O7S; molecular weight 475.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (42)

• Abdominal abscess
• Acute bacterial peritonitis
• Bacterial pneumonia
• Bacteroides Septic Abortion
• Colorectal Surgery Infection Prevention
• Community acquired pneumonia
• Complicated Bacterial Peritonitis
• Complicated Bacteroides Peritonitis
• Complicated E. Coli Peritonitis
• Complicated Skin and Skin Structure E. Coli Infection
• Complicated Skin and Skin Structure Infection
• Complicated Skin and Skin Structure Staphylococcus Aureus Infection
• Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
• Diabetic Foot Infection
• E. Coli Pyelonephritis
• E. Coli Septic Abortion
• Escherichia coli urinary tract infection
• Female genital tract infection
• Haemophilus influenzae pneumonia
• Infectious disease of abdomen
• Klebsiella Pyelonephritis
• Miscarriage with sepsis
• Moraxella Catarrhalis Pneumonia
• Peptostreptococcus infection
• Peptostreptococcus Septic Abortion
• Pneumococcal pneumonia
• Post-Op Gynecologic Infection due to Bacteroides
• Post-Op Gynecologic Infection due to Porphyromonas
• Post-Op Gynecologic Infection due to Prevotella
• Post-Op Gynecologic Infection, due to Streptococcus
• + 12 more

Off-label uses (2)

• Clostridium Perfringens Empyema
• Gas gangrene caused by clostridium perfringens

Contraindications (5)

• Acute nephropathy
• Kidney disease
• Lesion of brain
• Pseudomembranous enterocolitis
• Seizure disorder

Mechanism & targets

• Established pharmacologic class: Penem Antibacterial

Molecular targets (8)

Target	Gene	Action	Activity
Penicillin-binding protein 2	pbpA	unknown	—
Penicillin-binding protein 4	—	unknown	—
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5	dacA	unknown	—
Penicillin-binding protein 1	ponA	unknown	—
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6	dacC	unknown	—
D-alanyl-D-alanine carboxypeptidase DacB	dacB	inhibitor	—
Penicillin-binding protein 1A	mrcA	inhibitor	—
Penicillin-binding protein 1B	mrcB	inhibitor	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2002-04-18	EMA	—	Merck Sharp & Dohme Ltd
2001-11-21	FDA	—	MERCK SHARP DOHME

ATC classification

ATC code	Therapeutic hierarchy
J01DH03	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Macular degeneration	1710.8
Chronic sinusitis	510.1
Paraesthesia oral	471.3
Seizure	471.1
Vaginal flatulence	470.0
Female genital tract fistula	431.6
Proctitis	416.2
Vaginal discharge	411.6
Radiculopathy	400.7
Procedural pain	381.0
Hallucination	304.1
Oral candidiasis	302.7

Chemical structure

• Molecular formula: C₂₂H₂₅N₃O₇S
• Molecular weight: 475.52 g/mol
• CAS number: 153832-46-3
• InChIKey: JUZNIMUFDBIJCM-ANEDZVCMSA-N
• PubChem CID: 150610

C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C(O)=O)=C(N2C1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ertapenem used for?

DrugCentral lists the following indications for Ertapenem: Abdominal abscess, Acute bacterial peritonitis, Bacterial pneumonia, Bacteroides Septic Abortion, Colorectal Surgery Infection Prevention, Community acquired pneumonia, Complicated Bacterial Peritonitis and Complicated Bacteroides Peritonitis and others.

How does Ertapenem work?

Its molecular targets in DrugCentral include pbpA, Penicillin-binding protein 4, dacA and ponA.

When was Ertapenem first approved?

Ertapenem was first approved by the FDA in 2001.

What drug class does Ertapenem belong to?

Ertapenem is in the Penem Antibacterial class.

What is the chemical formula of Ertapenem?

Ertapenem has the molecular formula C22H25N3O7S and a molecular weight of 475.52 g/mol.

Sources

• DrugCentral drug card 1046 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1232 — compound record and bioactivity
• PubChem CID 150610 — chemical identifiers
• DrugBank DB00303 — drug record
• FDA UNII G32F6EID2H — substance identity
• DailyMed: FDA labels for Ertapenem — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.